Aarti Pharmalabs Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Topline dip masks underlying strength: Standalone revenue slipped ~5% YoY, but EBITDA grew 14% and PAT grew 9%, driven by a deliberate shift toward higher-margin regulated markets and CDMO work.
• CDMO order book supports 35–40% growth: With 60 active projects across 21 customers, management is confident in hitting its FY26 CDMO sales target, though revenue will remain second-half heavy.
• Xanthine capacity doubling to unlock a Rs. 1,000 crore segment: Brownfield expansion from 5,000 MT to 9,000 MT is on track for phased commissioning in H2 FY26, with a 2–3 year path to 80–90% utilization.
• Atali greenfield is the next leg of the story: Phase-1 mechanical completion is done; commercial production starts end of Q2 FY26, with a ramp-up through FY26 and significant contribution expected from FY27–28.
• What to watch next quarter: Whether the Ganesh Polychem JV reaches normal volumes, the pace of Atali’s commercial ramp-up, and any clarity on how US tariff policy evolves for pharma intermediates.

CDMO-CMO: The Growth Engine

• Order book visibility: The company is working with 21 customers on 60 active projects (33 commercial, 27 in development). Based on the current order book, management is on track to achieve its FY26 CDMO sales target and reiterated 35–40% growth guidance.
• Second-half lumpiness persists: CDMO revenue is structurally back-ended each year, and this pattern will continue even after Atali starts operations. Early-stage processing work done in Q1 will convert to invoicing in later quarters.
• China-shift tailwind: A lot of products have shifted from China to Aarti, with validations still underway. Once full-fledged supplier status is achieved, market share typically starts at 20–25% and can rise to 50% per molecule.
• Capability expansion: Newer offerings now include cyanation, continuous manufacturing, cryogenic reactions, hydrogenation, and HPAPIs (anti-cancer finished products), broadening the addressable innovator base.
• Atali as multi-site risk mitigation: New products will go directly to Atali; for existing products, 3–4 of 5–7 stages may shift there if customer approval is secured, with final stages staying at current sites. This provides overall risk mitigation.
• Long-term ambition: Management wants the CDMO segment to reach Rs. 800–1,000 crore (or USD 100 million) in 3–4 years, which would represent 25–33% of overall sales.

Gogri: "In 3-4 years, we want all segments to grow up to USD 100 million or Rs. 1,000 crore, whichever reaches faster, so that is what the target is."

Xanthine Derivatives: Capacity-Led Growth

• Brownfield expansion on track: Capacity is being expanded from 5,000 MT to 9,000 MT per annum, with phased commissioning across H2 FY26.
• Rs. 1,000 crore topline target: Management is confident of achieving Rs. 1,000 crore plus in Xanthine segment revenue in 2–3 years, with optimized capacity utilization of 7,500–8,000 MT (80–90% of 9,000 MT).
• Mix shift toward premium customers: The target is for 50% of sales to go to beverages and regulated-market customers, up from current levels, which should structurally lift segment margins.
• Pricing stability returns: Spot market prices are stable with no further drops seen. Raw material costs, which had caused past pricing pressure, have also come down and stabilized.
• Competitive moat intact: Aarti remains the only backward-integrated source independent of China from India offering Xanthine products at a reasonable price, a value proposition management emphasized directly.
• US tariff exemption holds: Xanthine derivatives including caffeine are under Annexure 2 of the US tariff list and are currently exempt.

Gogri: "Our value proposition to our customers is that we are the only backward integrated source independent of Chinese, from India who can offer them Xanthine products at a reasonable price."

API & Intermediates: Margin Over Volume

• Conscious volume sacrifice: API intermediate sales fell to ~Rs. 155 crores (from a ~Rs. 200 crore average) because management deliberately prioritized CDMO projects and captive intermediate consumption over external intermediate sales when capacity was constrained.
• Shipping disruption added friction: Unavailability of shipping space toward quarter-end left inventory higher than normal, further depressing reported sales.
• Margin protection through mix: When capacity is tight, the company cuts non-regulated market sales but continues serving high-margin regulated and ROW customers. A 10% capacity reduction may only reduce profit by a few percentage points.
• Patent expiry pipeline: In the next 2–3 years, several billion-dollar-plus products face patent expiries; capturing even 10–20% market share in a few of these would drive good API growth.
• Growth expectation: Year-on-year growth is expected in both API/intermediate and CDMO-CMO segments, with additional capacities freeing up in H2 FY26 or toward the last quarter.

Gogri: "If the capacity goes down by 10%, still the profit may not go down by the same amount. The profit may go down by only a few percentage points and vice versa is also true because we are anyway capturing all the high margin markets."

Margins & Mix

• Gross margin at a peak: Gross margins hit 57% (vs 51% QoQ, 48% YoY), driven by a product mix shift toward regulated markets, beverage customers, and export markets that yield better pricing than lower-price Xanthine segments. Inventory impact also contributed.
• Segment margin hierarchy: CDMO carries the highest margin, followed by Xanthine, then API. Management declined to disclose segment-level margin figures.
• Margin outlook stable with room to move: EBITDA margin from current levels can go plus or minus 2–3%. With new plants coming online, higher opex will weigh in the near term; next year can see higher growth.
• Accounting reclassification: Consumables like filter cloths, valves, and engineering items previously in cost of materials are now shown under other expenses. Cost of material consumed now consists only of raw material, packing material, and fuel. This change is like-to-like in published figures.
• Solar savings ahead: One more solar plant is coming via a power purchase agreement with a JV, which will deliver additional cost savings.

Capacity & Site Updates

• Atali greenfield Phase-1: Mechanical completion is done for Block 1; commercial production will commence toward the end of Q2 FY26 and will take until end of FY26 to ramp up to optimal utilization.
• Atali phased build-out: Every second year after the initial two years, additional blocks will be added. New products will go directly to Atali, while existing products may shift partially if customer approvals are secured.
• Existing site de-bottlenecking: One additional API line is being de-bottlenecked, alongside ongoing de-bottlenecking at existing sites, freeing up capacity in H2 FY26 or toward the last quarter.
• Utilization ceiling: At 80–85% reported utilization, the company considers itself fully occupied because it runs many products simultaneously across shared assets.
• Ganesh Polychem JV restart: The plant took a shutdown for modifications and restarted in July; normalcy in volume and demand is expected in the current quarter (Q2 FY26).

Gogri: "I think we have to bite the bullet once. So, that is what we will do in Atali."

Regulatory & Trade Environment

• US DMF and CEP count rising: US DMFs increased to 53 (from 50) and CEPs to 35 (from 31) in the last quarter, reflecting an expanding regulatory filing pipeline. Commercial APIs now stand at 60.
• Current tariff rules benign: APIs are not currently tariffed on exports to the US. Xanthine derivatives (caffeine and its source) are under the Annexure 2 exempt list. The company's sale condition is CIF, and it is not paying any tariff.
• Section 232 risk acknowledged but unquantified: If a 50% tariff were to emerge, management acknowledged "there will be some impact" but declined to speculate on absorption splits, noting contracts are largely FOB and the situation is hoped to resolve favorably.
• Aarti USA restructuring: Revenue of Aarti USA Incorporation is significantly down because distribution business previously done for Aarti Industries has shifted to Aarti Industries' own US subsidiary.

Guidance & Commitments

Key Metrics